Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 5 minute read Pharma Industry News Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after positive Phase III trial Akeso files gumokimab for NMPA review in ankylosing spondylitis. Find out how this move expands its autoimmune pipeline beyond oncology. bySrinathJanuary 20, 2026